NCT03441061 2026-02-17
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT05016947 2026-01-29
Venetoclax Plus Inotuzumab for B-ALL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05456698 2025-12-24
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Active not recruiting
NCT07238907 2025-11-25
A Multi-center Retrospective Study of INO Treating B-ALL
Ruijin Hospital
Active not recruiting
NCT05303792 2025-04-02
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03962465 2023-08-22
ALL-001
University of Virginia
Phase 1 Active not recruiting